Full article: https://www.ajronline.org/doi/abs/10.2214/AJR.20.24567
Patients with borderline resectable and locally advanced pancreatic cancer receiving neoadjuvant therapy can have results comparable to patients with resectable tumor at presentation, however some patients have early recurrence after neoadjuvant therapy and resection. Jordan Perchik, MD discusses a new AJR study in which a team of radiologists evaluate multiple imaging parameters and tumor metrics to assess for characteristics to predict pathologic response prior to resection.
View all episodes
By AJR
4.6
4545 ratings
Full article: https://www.ajronline.org/doi/abs/10.2214/AJR.20.24567
Patients with borderline resectable and locally advanced pancreatic cancer receiving neoadjuvant therapy can have results comparable to patients with resectable tumor at presentation, however some patients have early recurrence after neoadjuvant therapy and resection. Jordan Perchik, MD discusses a new AJR study in which a team of radiologists evaluate multiple imaging parameters and tumor metrics to assess for characteristics to predict pathologic response prior to resection.
38,470 Listeners
30,686 Listeners
25,887 Listeners
8,715 Listeners
4,365 Listeners
89 Listeners
28 Listeners
112,362 Listeners
56,459 Listeners
9,533 Listeners
10,233 Listeners
30 Listeners
204 Listeners
16,145 Listeners
42 Listeners